CZCharles Zhao

Charles Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Charles Zhao has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew Ip

    John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, United States

    3 shared publications
  • Gee Youn (Geeny) Kim

    Affiliations Division of Oncology, Hackensack University Medical Center, Hackensack, NJ, United States of America, Department of Pharmacy Practice, Ernest Mario School of Pharmacy at Rutgers University, Piscataway, NJ, United States of America

    3 shared publications
  • Alexandra Della Pia

    Affiliations Division of Oncology, Hackensack University Medical Center, Hackensack, NJ, United States of America, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, United States of America

    2 shared publications
  • Amolika Gupta

    Affiliation Department of Oncology, Hackensack Meridian School of Medicine, Nutley, NJ, United States of America

    2 shared publications
  • Anamta Contractor

    Affiliation St. George’s University School of Medicine, Grenada, West Indies

    2 shared publications
  • Andre Goy

    John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey

    2 shared publications

Latest Publications

  • Open Access

    Anti-spike antibody response to the COVID vaccine in lymphoma patients

    by Alexandra Della Pia, Gee Youn (Geeny) Kim, Andrew Ip, Jaeil Ahn, Yanzhi Liu, Simone Kats, Michael Koropsak, Brittany Lukasik, Anamta Contractor, Krushna Amin, et al.

    Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an antibody response after COVID infection. This is a retrospective study of adult lymphoma patients who received the COVID vaccine between 12/1/2020 and 11/30/2021. The primary endpoint was a positive anti-COVID spike protein antibody level following the primary COVID vaccination series. The primary vaccination series was defined as 2 doses of the COVID mRNA vaccines or 1 dose of the COVID adenovirus vaccine. Subgroups were compared using Fisher’s exact test, and unadjusted and adjusted logistic regression models were used for univariate and multivariate analyses. A total of 243 patients were included in this study; 72 patients (30%) with indolent lymphomas; 56 patients (23%) with Burkitt’s, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma (PMBL) combined; 55 patients (22%) with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL); 44 patients (18%) with Hodgkin and T-cell lymphomas (HL/TCL) combined; 12 patients (5%) with mantle cell lymphoma; and 4 patients (2%) with other lymphoma types. One-hundred fifty-eight patients (65%) developed anti-COVID spike protein antibodies after completing the primary COVID vaccination series. Thirty-eight of 46 (83%) patients who received an additional primary shot and had resultant levels produced anti-COVID spike protein antibodies. When compared to other lymphoma types, patients with CLL/SLL had a numerically lower seroconversion rate of 51% following the primary vaccination series whereas patients with HL/TCL appeared to have a robust antibody response with a seropositivity rate of 77% (p = 0.04). Lymphoma patients are capable of mounting a humoral response to the COVID vaccines. Further studies are required to confirm our findings, including whether T-cell immunity would be of clinical relevance in this patient population.


  • Open Access

    Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era

    by Alexandra Della Pia, Charles Zhao, Parul Jandir, Amolika Gupta, Mark Batistick, Gee Youn (Geeny) Kim, Yi Xia, Jaeil Ahn, Gabriella Magarelli, Brittany Lukasik, et al.

    Lymphoma patients are at greater risk of severe consequences from COVID-19 infection, yet most reports of COVID-19-associated outcomes were published before the advent of COVID-19 vaccinations and monoclonal antibodies (mAbs). In this retrospective study, we report the real-world outcomes of 68 lymphoma or CLL patients who developed COVID-19 infection during the omicron surge in the US. We found that 34% of patients were hospitalized as a result of COVID-19 infection. The death rate due to COVID-19 was 9% (6/68) in the overall population and 26% (6/23) in hospitalized patients. During the preintervention COVID-19 era, the mortality rate reported in cancer patients was 34%, which increased to 60.2% in hospitalized patients. Thus, the death rates in our study were much lower when compared to those in cancer patients earlier in the pandemic, and may be attributed to modern interventions. In our study, 60% (18/30) of patients with serology data available did not develop anti-COVID-19 spike protein antibodies following vaccination. Most patients (74%, 17/23) who were hospitalized due to COVID-19 infection did not receive COVID-19 mAb treatment. Our results pointed to the importance of humoral immunity and the protective effect of COVID-19 mAbs in improving outcomes in lymphoma patients.


  • Open Access

    Production of anti-spike antibodies in response to COVID vaccine in lymphoma patients

    by Alexandra Della Pia, Gee Youn (Geeny) Kim, Andrew Ip, Jaeil Ahn, Yanzhi Liu, Simone Kats, Michael Koropsak, Brittany Lukasik, Anamta Contractor, Krushna Amin, et al.

    Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an antibody response after COVID infection. There is limited data on the efficacy of the COVID vaccines in lymphoma patients, and to suggest the optimal timing of vaccination to elicit immunity in patients receiving immunochemotherapy. This is a retrospective study of adult lymphoma patients who received the COVID vaccine between 12/1/2020 and 11/30/2021. The primary endpoint was a positive anti-COVID spike protein antibody titer following the primary COVID vaccination series. The primary series was defined as 2 doses of the COVID mRNA vaccines or 1 dose of the COVID adenovirus vaccine. Subgroups were compared using Fisher’s exact test, and unadjusted and adjusted logistic regression models were used for univariate (UVA) and multivariate (MVA) analyses. A total of 243 patients were included in this study; 72 patients (30%) with indolent lymphomas; 56 patients (23%) with Burkitt’s, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma (PMBL) combined; 55 patients (22%) with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL); and 44 patients (18%) with Hodgkin and T-cell lymphomas (HL/TCL) combined. One-hundred fifty-eight patients (65%) developed anti-COVID spike protein antibodies after completing the primary COVID vaccination series. Thirty-eight of 46 (83%) patients who received an additional primary shot and had resultant levels produced anti-COVID spike protein antibodies. When compared to other lymphoma types, patients with CLL/SLL had a numerically lower seroconversion rate of 51% following the primary series whereas patients with HL/TCL appeared to have a robust antibody response with a seropositivity rate of 77% (p=0.04). Lymphoma patients are capable of mounting a humoral response to the COVID mRNA vaccines. Further studies are required to confirm our findings, including whether T-cell immunity would be of clinical relevance in this patient population.